Next Article in Journal
18 F-FDG PET/CT in Extensive Graft-Versus-Host Disease of the Gastrointestinal Tract Following Autologous Stem Cell Transplantation
Previous Article in Journal
Selenium and Selenoproteins in Immune Mediated Thyroid Disorders
Article Menu
Issue 4 (December) cover image

Export Article

Open AccessArticle
Diagnostics 2018, 8(4), 71;

Validation of a Novel Modified Aptamer-Based Array Proteomic Platform in Patients with End-Stage Renal Disease

Department of Medicine-Nephrology, University of Tennessee Health Science Center, Memphis, TN 38103, USA
Department of Medicine, University of California, Irvine, CA 92868, USA
Department of Epidemiology, Biostatistics and Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
Division of Renal Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
Johns Hopkins Bloomberg School of Public Health Welch Center for Prevention, Epidemiology, and Clinical Research, Baltimore, MD 21205, USA
Nephrology Section, Memphis VA Medical Center, Memphis, TN 38104, USA
Author to whom correspondence should be addressed.
Received: 15 August 2018 / Revised: 24 September 2018 / Accepted: 2 October 2018 / Published: 8 October 2018
(This article belongs to the Section Pathology and Molecular Diagnostics)
Full-Text   |   PDF [637 KB, uploaded 8 October 2018]   |  


End stage renal disease (ESRD) is characterized by complex metabolic abnormalities, yet the clinical relevance of specific biomarkers remains unclear. The development of multiplex diagnostic platforms is creating opportunities to develop novel diagnostic and therapeutic approaches. SOMAscan is an innovative multiplex proteomic platform which can measure >1300 proteins. In the present study, we performed SOMAscan analysis of plasma samples and validated the measurements by comparison with selected biomarkers. We compared concentrations of SOMAscan-measured prostate specific antigen (PSA) between males and females, and validated SOMAscan concentrations of fibroblast growth factor 23 (FGF23), FGF receptor 1 (FGFR1), and FGFR4 using Enzyme-Linked immunosorbent assay (ELISA). The median (25th and 75th percentile) SOMAscan PSA level in males and females was 4304.7 (1815.4 to 7259.5) and 547.8 (521.8 to 993.4) relative fluorescence units (p = 0.002), respectively, suggesting biological plausibility. Pearson correlation between SOMAscan and ELISA was high for FGF23 (R = 0.95, p < 0.001) and FGFR4 (R = 0.69, p < 0.001), indicating significant positive correlation, while a weak correlation was found for FGFR1 (R = 0.13, p = 0.16). In conclusion, there is a good to near-perfect correlation between SOMAscan and standard immunoassays for FGF23 and FGFR4, but not for FGFR1. This technology may be useful to simultaneously measure a large number of plasma proteins in ESRD, and identify clinically important prognostic markers to predict outcomes. View Full-Text
Keywords: end-stage renal disease; SOMAscan; validation; biomarker end-stage renal disease; SOMAscan; validation; biomarker

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Han, Z.; Xiao, Z.; Kalantar-Zadeh, K.; Moradi, H.; Shafi, T.; Waikar, S.S.; Quarles, L.D.; Yu, Z.; Tin, A.; Coresh, J.; Kovesdy, C.P. Validation of a Novel Modified Aptamer-Based Array Proteomic Platform in Patients with End-Stage Renal Disease. Diagnostics 2018, 8, 71.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Diagnostics EISSN 2075-4418 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top